ReviewGut microbes2020
Probiotics in the next-generation sequencing era.
Review in Gut microbes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Safety and Next-Generation Probiotic Potential of Mitsuokella multacida AGMB01124 Newly Isolated from Healthy Swine Feces.Probiotics and antimicrobial proteins · 2026Article
- Gut-Heart Axis in HFpEF: The Emerging Role of Microbiome-Driven Inflammation and Endothelial Dysfunction.Biomolecules · 2026Review
- Balancing harm and harmony: Evolutionary dynamics between gut microbiota-derived flagellin and TLR5-mediated host immunity and metabolism.Virulence · 2025Review
- Evaluating the Adjuvant Therapeutic Effects of Probiotic StrainsAnimals : an open access journal from MDPI · 2025Article
- Effects of Athletic Nutritional Supplements on the Human Gut Microbiota: A Narrative Review.Nutrients · 2025Review
- A Balancing Act-20 Years of Nutrition and Health Claims Regulation in Europe: A Historical Perspective and Reflection.Foods (Basel, Switzerland) · 2025Article
- Novel therapeutic strategies and recent advances in gut microbiota synergy with nanotechnology for colorectal cancer treatment.Materials today. Bio · 2025Review
- Action and immunomodulatory mechanisms, formulations, and safety concerns of probiotics.Bioscience of microbiota, food and health · 2025Review
- Multi-omics analysis reveals the efficacy of two probiotic strains in managing feline chronic kidney disease through gut microbiome and host metabolome.Frontiers in veterinary science · 2025Article
- Next-Generation Probiotics and Chronic Diseases: A Review of Current Research and Future Directions.Journal of agricultural and food chemistry · 2024Review
- The role ofFood science and biotechnology · 2024Review
- Modulation of Gut Microbial Biomarkers and Metabolites in Cancer Management by Tea Compounds.International journal of molecular sciences · 2024Review
- Exploring the Preventive and Therapeutic Mechanisms of Probiotics in Chronic Kidney Disease through the Gut-Kidney Axis.Journal of agricultural and food chemistry · 2024Review
- Promiscuous, persistent and problematic: insights into current enterococcal genomics to guide therapeutic strategy.BMC microbiology · 2024Review
- Gut microbiota influence frailty syndrome in older adults: mechanisms and therapeutic strategies.Biogerontology · 2024Review
- Machine learning-enhanced assessment of potential probiotics from healthy calves for the treatment of neonatal calf diarrhea.Frontiers in microbiology · 2024Article
- What Makes the Gut-Lung Axis Working? From the Perspective of Microbiota and Traditional Chinese Medicine.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Review
- Approach to the diagnosis and management of dysbiosis.Frontiers in nutrition · 2024Review
- Characterization of TwoCells · 2023Article
- Natural Ingredients to Improve Immunity.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Technological developments, including massively parallel DNA sequencing, gnotobiotics, metabolomics, RNA sequencing and culturomics, have markedly propelled the field of microbiome research in recent years. These methodologies can be harnessed to improve our in-depth mechanistic understanding of basic concepts related to consumption of probiotics, including their rules of engagement with the indigenous microbiome and impacts on the human host. We have recently demonstrated that even during probiotic supplementation, resident gut bacteria in a subset of individuals resist the mucosal presence of probiotic strains, limiting their modulatory effect on the microbiome and on the host gut transcriptional landscape. Resistance is partly alleviated by antibiotics treatment, which enables probiotics to interact with the host at the gut mucosal interface, although rather than promoting reconstitution of the indigenous microbiome and of the host transcriptional profile, they inhibit these components from returning to their naïve pre-antibiotic configurations. In this commentary, we discuss our findings in the context of previous and recent works, and suggest that incorporating the state-of-the-art methods currently utilized in microbiome research into the field of probiotics may lead to improved understanding of their mechanisms of activity, as well as their efficacy and long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.